TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Present with type 2 diabetes mellitus~* Have been receiving twice-daily premixed insulin therapy with or without metformin and/or alpha-glucosidase inhibitors, for at least six months prior to study entry~* Have Haemoglobin A1c (HbA1c) \>7.0% and \<12.0%~Exclusion Criteria:~* Within the last 3 months prior to entry into the study, are taking any non-permitted glucose-lowering agents, or are taking any non-permitted oral antihyperglycaemic medications~* Are pregnant or intend to become pregnant during the course of the study, or are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable.~* Are women who are breastfeeding.~* Have an irregular sleep/wake cycle (for example, participants who sleep during the day and work during the night).~* Do not regularly consume three meals per day.~* Have a body mass index \>35 kilogram per square meter (kg/m\^2).~* Have had more than one episode of severe hypoglycaemia within 24 weeks prior to entry into the study.~* Have cardiac disease with a functional status that is Class III or IV~* Have a history of renal or liver disease~* Have used less than or equal to 20 Units per day (U/day) of insulin during the past 90 days for more than 14 days (accumulated).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Premixed Insulin (Type: EXPERIMENTAL): Twice daily (before breakfast and lunch) insulin lispro mix 50 (50% insulin lispro, 50% insulin lispro protamine suspension \[LM50\]) and once daily (before dinner) insulin lispro mix 25 (25% insulin lispro, 75% insulin lispro protamine suspension \[LM25\])
- Basal-Bolus (Type: ACTIVE_COMPARATOR): Once daily (bedtime) insulin glargine and three pre-meal insulin lispro

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Muslim, with type 2 diabetes mellitus~* Intends to fast during the month of Ramadan~* Hemoglobin A1c (HbA1c) ≤10% at screening~* On a stable dose of a SU drug (glibenclamide, glimepiride, or gliclazide), for at least three months, with or without metformin therapy at a stable dose~Exclusion Criteria:~* Type 1 diabetes mellitus~* Pregnant or breast feeding or with gestational diabetes~* Hypersensitivity or contraindication to dipeptidyl peptidase-4 (DPP-4) treatment~* Serum creatinine ≥1.5 mg/dL (males), ≥1.4 mg/dL (females)~* History of severe hypoglycemia (defined as a hypoglycemic event requiring the assistance of another individual, and/or resulting in a emergency department admission, physician office visit and/or hospitalization)~* Any use of insulin (prior to or during Ramadan)~* Use of any class of oral antidiabetic therapy other than an SU or metformin~* Current participation in another interventional study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Sitagliptin 100mg taken orally once daily with or without metformin
- Sulfonylurea Therapy (Type: ACTIVE_COMPARATOR): Usual sulfonylurea therapy with or without metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female out-patients age ≥ 18 and ≤ 80 years.~* A clinical diagnosis of bilateral BEB characterized by spontaneous, spasmodic, intermittent or persistent involuntary contractions of orbicular oculi muscles.~* A need for injection of BTX defined as a Jankovic Rating Scale \[JRS\] severity subscore ≥ 2.~* Treatment-naïve subject defined as at least 12 months without BTX of any serotype for the treatment of BEB before administration of IP.~Exclusion Criteria:~* Subject with any previous unsuccessful treatment with BTX of any serotype for the treatment of BEB.~* Atypical variant of BEB (e.g., apraxia of the eyelid opening) caused by inhibition of levator palpebrae muscle.~* Neuroleptic-induced blepharospasm.~* Myotomy or denervation surgery in the affected muscles (e.g., peripheral denervation, spinal cord stimulation) and surgery in the upper face.~* Generalized disorders of muscles activity (e.g., myasthenia gravis in particular ocularis, Lambert-Eaton-Syndrome, amyotrophic lateral sclerosis) or any other significant neuromuscular dysfunction which might interfere with the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IncobotulinumtoxinA (Xeomin) 25U per eye (Type: EXPERIMENTAL): Main Period: one injection session, 25 Units per eye. Open-Label Extension: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
- IncobotulinumtoxinA (Xeomin) 12.5U per eye (Type: EXPERIMENTAL): Main Period: one injection session, 12.5 Units per eye. Open-Label Extension Period: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
- Placebo (Type: PLACEBO_COMPARATOR): Main Period: Placebo to IncobotulinumtoxinA (Xeomin)(12.5 or 25U/eye), one injection session.~Open-Label Extension: IncobotulinumtoxinA (Xeomin), one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)~* The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study~* Male or female, age greater than or equal to 18 years at the time of signing informed consent~* Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion~* Available and documented HbA1c value less than or equal to 12 weeks prior to initiation of semaglutide treatment~Exclusion Criteria:~* Previous participation in this study. Participation is defined as having given informed consent in this study~* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation~* Treatment with any investigational drug within 90 days prior to enrolment into the study~* Hypersensitivity to semaglutide or to any of the excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Semaglutide (Type: None): Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects between the age of 10 and 18 years (inclusive) who received a dose of Boostrix and who have safety follow-up information available

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Boostrix cohort (Type: None): None
- Historical Td cohort (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CD22 expression~* Adequate liver and renal functions~Exclusion Criteria:~* Isolated extramedullary disease~* Active Central Nervous System \[CNS\] disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): None
- Arm B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~\* Diagnosis of B-cell chronic lymphocytic leukemia (CLL)~- Early-stage, biologically high-risk disease defined by the following criteria:~* Rai stage 0-II (does not meet standard NCI-sponsored Working Group criteria for treatment)~* Clinical and phenotypic features manifested in the peripheral blood, including the following:~  * Minimum threshold peripheral blood lymphocyte count of \> 5,000/mm³~ * Small-to-moderate peripheral blood lymphocytes with ≤ 55% prolymphocytes~ * Monoclonality of B lymphocytes by immunophenotypic evaluation, demonstrating co-expression of CD19, CD5, and CD23 antigens, surface expression of CD20 and CD52, and B-cell monoclonal population defined by light-chain exclusions~* Poor prognosis demonstrated by ≥ 1 of the following high-risk parameters:~  * Unmutated human immunoglobulin variable region heavy chain (IgVH) gene and CD38 expression (≥ 30% cells positive on flow cytometry) OR unmutated IgVH ZAP-70 expression (≥ 20% cells positive on flow cytometry) = 11q- = 17p-~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Creatinine ≤ 1.5 times upper limit of normal (ULN)~* Total bilirubin ≤ 3.0 times ULN OR direct bilirubin ≤ 1.5 times ULN~* AST ≤ 3.0 times ULN (unless due to hemolysis or CLL)~* Hemoglobin ≥ 9.0 g/dL~* No New York Heart Association class III-IV heart disease~* No myocardial infarction within the past month~* No uncontrolled infection~* No active HIV infection~* No evidence of autoimmune hemolytic anemia, immune thrombocytopenia, or pure red blood cell aplasia~* No other active primary malignancy requiring treatment or limiting survival to less than 2 years~PRIOR CONCURRENT THERAPY:~* No prior treatment for CLL~* Prior corticosteroids allowed~* No prior radiotherapy~* More than 4 weeks since prior major surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab + Rituximab (Type: EXPERIMENTAL): Alemtuzumab 30mg Monday, Wednesday, and Friday x 5 weeks, Rituximab 375/mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects from 16 to 80 years, inclusive. Subjects under 20 years may only be included where legally permitted and ethically accepted~* Subjects with refractory epilepsy with partial onset seizure classifiable according to the International League Against Epilepsy (ILAE).~* Subjects having at least 2 partial onset seizures whether or not secondarily generalized during the 8 weeks historical baseline preceding V1 according to ILAE classification~* Subjects having at least 1 partial onset seizures whether or not secondarily generalized per 4 weeks preceding V2 according to ILAE classification~* Subjects with each interval of partial onset seizures less than 6 weeks during entire 12 weeks (8 weeks preceding V1 and 4 weeks preceding V2)~* Subjects being uncontrolled while treated by 1 to 3 permitted concomitant AEDs.~* Permitted concomitant AEDs having been stable and at optimal dosage for the subject from at least 4 week before V1 and during 4 weeks preceding V2 and expected to be kept stable during the Treatment Period.~Exclusion Criteria:~* Subjects presenting any generalized epilepsies classified as type II according to the ILAE classification (ref to publication from 1981)~* Subjects suffering from epilepsies and syndromes undetermined whether focal or generalized (classification III according to the ILAE classification)~* Subjects suffering from special syndromes (classification IV according to the ILAE classification)~* History or occurring only in clusters (too frequently or indistinctly separated to be reliably counted) before V2.~* Presence of exclusively type IA non-motor seizures.~* History or presence of status epilepticus within last 3 months preceding V1 or during Baseline~* History or presence of known pseudo-seizures~* Subjects who are currently on vigabatrin. (Subjects who received vigabatrin in the past and have a normal visual field test are allowed.)~* Subject taking 1 or more of the following medications on a regular basis within 28 days prior to Visit 1: antipsychotics drugs, and psychostimulant (amphetamine derivatives)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (Type: EXPERIMENTAL): 250 mg and 500 mg levetiracetam tablet; titration from 1000 mg/day (500 mg bid) to 3000 mg/day (1500 mg bid) levetiracetam with treatment duration up to 52 weeks
- Topiramate (Type: ACTIVE_COMPARATOR): 25 mg and 100 mg topiramate tablet; titration from 100 mg/day (50 mg bid) to 400 mg/day (200 mg bid) topiramate with treatment duration up to 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy adults between the ages of 18 and 55 years old.~2. Male or female~Exclusion Criteria:~1. Presence of clinically significant cardiovascular, endocrine, hematopoietic, hepatic, neurologic, psychiatric, or renal disease or pregnancy.~2. Presence or history of drug or alcohol abuse.~3. The use of concomitant medications, which are known to affect ESL or Carbamazepine or the use of any concomitant medications that may alter cognitive function (see Section VII.E for a partial list).~4. Use of oral contraceptive hormones or other medications that could be affected by ESL or Carbamazepine.~5. Prior adverse reaction to or prior hypersensitivity to either study medication or to related compounds.~6. Prior participation in studies involving anticonvulsant medications.~7. Subjects who have received any investigational drug within the previous thirty days.~8. Subjects with IQ \< 70 as determined by the Peabody Picture Vocabulary Test.~9. Presence of HLA B\*1502 in subjects of Asian descent; this will be obtained at screening in subjects of Asian descent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Eslicarbazepine (Type: EXPERIMENTAL): Randomized to eslicarbazepine 800mg po bid in crossover design.
- Carbamazepine (Type: EXPERIMENTAL): Randomized to carbamazepine 400mg po bid in crossover design.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Rheumatoid arthritis of \>/= 1 year duration~* Mild to moderate disease activity at screening (DAS 28 \</= 4.5 and \>2.6)~* On methotrexate treatment for at least 12 weeks, at stable oral dose of (10)15 mg to 25 mg/week for at least 6 weeks prior to Day 1~* Body weight \</= 150 kg~* Oral corticosteroids must have been at stable dose (maximum 10 mg/day) for at least 25 out of 28 days prior to baseline~Exclusion Criteria:~* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after baseline~* Rheumatic autoimmune disease other than rheumatoid arthritis~* Functional class IV American College of Rheumatology (ACR) Classification~* Prior history of or current inflammatory joint disease other than rheumatoid arthritis~* Treatment with a biologic agent at any time prior to baseline~* Treatment with traditional DMARDs other than methotrexate within 1 month (for leflunomide 3 months) prior to baseline~* Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline~* Previous treatment with tocilizumab~* Pregnant or lactating women~* Uncontrolled disease states, such as asthma, psoriasis or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids~* Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections~* History of or currently active primary or secondary immunodeficiency~* Evidence of active malignant disease, malignancies diagnosed within the previous 5 years~* Active tuberculosis requiring treatment within the previous 3 years~* Positive for HIV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A Methotrexate (Type: ACTIVE_COMPARATOR): None
- B Methotrexate Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* a gestational age \< 32 weeks~* a birth weight \< 1500g~* a postnatal age between 48 and 96 hours, a respiratory distress requiring more than 25 % of oxygen supplementation~* an echocardiographic evidence of left to right significant shunting PDA~Exclusion Criteria:~* a right-to-left shunting~* major congenital anomalies~* IVH grade 3-4~* a tendency to bleed (defined by the presence of blood in the endotracheal aspirate, gastric aspirate, stools or urines and / or oozing from puncture sites)~* a serum creatinine level \>140µmol/l, a serum urea nitrogen \> 14 µmol/l and a platelet count \< 60000/mm3.

- Gender: ALL
- Minimum Age: 48 Hours
- Maximum Age: 96 Hours
- Healthy Volunteers: f

Study Arms:
- I (Type: ACTIVE_COMPARATOR): None
- O (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete